{"id":"3b8aea702800","type":"article","url":"https://hartvaat.nl/2026/02/25/uitkomsten-van-hartfalen-naar-ejectiefractie-het-esc-hf-iii-register/","title":"Uitkomsten van hartfalen naar ejectiefractie: het ESC HF III Register","title_en":"Outcomes of heart failure with reduced, mildly reduced, or preserved ejection fraction: the ESC HF III registry.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":["hfmref","hfpef","hfref","step-hfpef"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf1074","source_url":"https://doi.org/10.1093/eurheartj/ehaf1074","authors":["Lars H Lund","Aldo P Maggioni","Maria G Crespo-Leiro","Cecile Laroche","Israel Gotsman","Belma Pojskic","Eleonora B Vataman","Lucica Grigorica","Hamayak Sisakian","Duska Glavas","Dulce A Brito","Stefan Anker","Ovidiu Chioncel","Gerasimos Filippatos","Mitja Lainscak","Theresa A McDonagh","Alexandre Mebazaa","Massimo Piepoli","Frank Ruschitzka","Gianluigi Savarese","Petar M Seferović","Marco Metra","Giuseppe Rosano"],"significance":8,"published":"2026-02-25","source_date":"2026-02-25","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfmref-hartfalen-met-matig-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"The ESC Heart Failure III Registry followed 10,162 patients across 41 countries with HFrEF, HFmrEF, and HFpEF, providing contemporary real-world data on in-hospital and 1-year outcomes across the heart failure spectrum in routine clinical practice.","created":"2026-07-03T10:25:06Z","updated":"2026-07-03T18:38:12Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Het ESC HF III Register volgde 10.162 patiënten uit 41 landen met hartfalen (HFrEF, HFmrEF en HFpEF). Het register biedt gedetailleerde gegevens over in-hospitaal- en éénjaarsuitkomsten, met aandacht voor doodsoorzaak-specifieke resultaten in de hedendaagse Europese hartfalenpopulatie.","abstract_original":"BACKGROUND AND AIMS: To assess in-hospital and 1-year cause-specific outcomes in the contemporary European Society of Cardiology (ESC) Heart Failure (HF) III Registry. METHODS: Patients were enrolled in European or ESC affiliated countries and characterized in detail regarding clinical characteristics and cause-specific outcomes. RESULTS: Between 1 November 2018 and 31 December 2020, 10,162 patients were enrolled from 220 centres in 41 countries. Of these, 39% had acute HF ('AHF', age 70 [62-79] years, 36% women) and 61% had out-patient visit for HF ['out-patient HF', age 66 (58-75) years, 33% women]. Overall, 58% had HF with reduced ejection fraction (HFrEF), 17% HF with mildly reduced ejection fraction (HFmrEF), and 25% HF with preserved ejection fraction (HFpEF). In AHF, median [interquartile range (IQR)] duration of hospitalization was 9 (6-14) days, and 5.1% died in hospital (HFrEF 5.2%; HFmrEF 4.8%, HFpEF 3.4%). In AHF discharged alive and in out-patient HF, after a median (IQR) follow-up of 376 (360-432) days, all-cause, cardiovascular (CV), and unknown-cause mortality rates per 100 patient-years were as follows: AHF HFrEF: 19, 13, and 3.0 per 100 patient-years. The corresponding numbers were in AHF HFmrEF: 22, 11, and 6.3; AHF HFpEF: 16, 7.0, and 4.7; out-patient HFrEF: 6.6, 4.3, and 0.9; out-patient HFmrEF: 4.0, 2.6, and 0.8; out-patient HFpEF: 3.9, 1.7, and 1.2. At least one (re-)hospitalization for HF was experienced in 44% AHF HFrEF, 42% AHF HFmrEF, 36% AHF HFpEF, 21% out-patient HFrEF, 14% out-patient HFmrEF, and 18% out-patient HFpEF. CONCLUSIONS: In HF in Europe and affiliated countries, in-hospital mortality was 5.1% and greater with lower ejection fraction. Among hospital survivors and out-patients over 1 year of follow-up, event rates per 100 patient-years varied for death, 3.9-22, CV death 1.7-13, and unknown cause of death 0.8-6.3. The percent of patients that were (re-)hospitalized for HF at least once over 1-year follow-up ranged 14-44% and was twice as high post-AHF compared with post-out-patient visit."}